Objective —to analyze the efficiency of a regimen involving doxorubicin + dacarbazine in the treatment of patients with unresectable desmoid fibromas (DFs) of the trunk and extremities. Subject and methods. Seventy-three patients with primary and recurrent extraabdominal DFs were treated in 2013 to 2018. Surgical treatment was performed in 40 patients. In 33 patients, the tumor was recognized unresectable; in this case, various medical treatment options were used. Fourteen patients received anti-estrogen hormone therapy; 16 patients had chemotherapy with vinblastine + methotrexate; 16 took vinorelbine + methotrexate, 7 used doxorubicin + dacarbazine, and 4 received imatinib. The indications for chemotherapy with a regimen involving doxorubicin + dacarbazine were disease progression during or after the use of vinblastine and methotrexate, hormonal therapy, and the need to achieve a clinical response in a shorter time period. Results. The clinical efficacy rates were 86%. Six patients with a stabilized or partial response were followed up for 6—108 months. The median follow-up period was 19 months. Six months after therapy termination, the progression of the process was noted in one patient, which required the resumption of drug treatment and the prescription of imatinib therapy (radiotherapy had been previously performed). The remaining 5 patients showed no negative changes, such as enlarged tumor nodules or more severe pain, in the follow-up period of 6 to 108 months. Conclusion. Chemotherapy with doxorubicin and dacarbazine has been observed to be highly effective in treating unresectable extraabdominal DFs; however, the use of anthracyclines is justified only when less toxic therapeutic options are ineffective and when the disease is aggressive.